89bio

We're thrilled to announce our participation in three prestigious upcoming healthcare investor conferences. It's an exciting time as we share our progress and connect with other leaders in the industry. Here's where you can find us: 📍Wells Fargo Healthcare Conference in Boston on September 5th at 12:45 pm ET.   📍HC Wainwright in New York on September 9th at 11:30 am ET. 📍Cantor Fitzgerald in New York on September 17th at 11:30 am ET.  We look forward to sharing the progress on our clinical development programs. Stay tuned for updates and breakthroughs from #Team89bio! Learn more: https://lnkd.in/gH_q5Ki9   #Biotech #StartUp #Innovation #MASH #SHTG

Severe hypertriglyceridemia (#SHTG) is a condition where triglyceride levels exceed 500 mg/dL and it can pose serious health risks, including acute #pancreatitis, which is a painful and potentially dangerous inflammation of the pancreas. SHTG is a primary focus area at 89bio. Learn more about the condition and how we are addressing this #CardioMetabolic disease: https://lnkd.in/gE7AwYWu #HeartHealth #Innovation

 We are thrilled to announce the appointment of Francis Sarena as 89bio’s Chief Operating Officer. With over 25 years of experience, Mr. Sarena brings extensive leadership, strategic, and operational expertise to our growing team. Mr. Sarena will be a valuable asset as we advance our Phase 3 clinical program of our FGF21 analog for the treatment of #MASH and #SHTG. To learn more about Mr. Sarena and this exciting addition to our leadership team, visit: https://lnkd.in/gUAjBNME

Today, 89bio reported their Q2 2024 financial earnings and business update. We're thrilled to share our latest achievements and milestones – and would like to extend an extra thank you for all our incredible team’s hard work and dedication; we've seen remarkable progress and growth this quarter. Read our release to learn more: https://lnkd.in/gCCJavti

Today, we welcome Charles McWherter, Ph.D., to the 89bio Board of Directors! Dr. McWherter's robust expertise in drug development and knowledge of liver inflammation and fibrosis will be an indispensable asset as we move forward in our #MASH and #SHTG Phase 3 programs.  To learn more about Dr. McWherter, visit: https://lnkd.in/g_q-QfZU. We are excited to have him on board.

We remain confident that our investigational #FGF21 analog has the potential to be a best-in-class therapeutic for patients with #MASH and #SHTG based on completed studies. Did you know that FGF21 is an endogenous hormone that functions as a master metabolic regulator that has the potential to address underlying metabolic issues that drive liver and #CardioMetabolic diseases? The science speaks for itself -- learn more about our FGF21 analog’s mechanism of action: https://lnkd.in/gCZYq9u

When you're a company focused on redefining what's possible for patients with #CardioMetabolic Diseases, it's essential to pause and recalibrate. Earlier this month, 89bio employees from around the world gathered in our San Francisco office for our quarterly All Company Week.   Throughout the week, we collaborated on new ideas, reflected on old ones, and recommitted to our mission of developing therapies that make a meaningful difference for patients. We've come a long way, and we're excited about how far we can go.   At our company, we’re empowered to show up as our full authentic selves - that's the #89way.   #Innovation #WorkCulture

In May, Dr. Arun J. Sanyal (Virginia Commonwealth University) joined 89bio to discuss the unmet need and current treatment landscape for advanced metabolic dysfunction-associated steatohepatitis (#MASH) patients with fibrosis and compensated cirrhosis. During his presentation, Dr. Sanyal discusses the importance of treatment options that have anti-fibrotic effects which is showcased in this clip. For more information and latest research on the potent anti-fibrotic effects of our investigational FGF21 analog, listen to the full presentation: https://lnkd.in/gMyuxHZW

Exciting growth is happening at 89bio! We're currently seeking dynamic individuals who pursue excellence to benefit patients, embody an entrepreneurial mindset, and are eager to be driven by science as we continue to innovate for #CardioMetabolic diseases. Discover what makes the 89bio way unique and see if you’d be a good candidate for one of our open roles: https://lnkd.in/gbijsSjq #the89Way #BioPharma #Recruitment #JobOpening #NewJobs

As we enter the second half of 2024, we are more steadfast than ever in our commitment to delivering innovative therapies for liver disease patients. Last month, we initiated our second Phase 3 clinical trial in #MASH in our ENLIGHTEN program. These two clinical trials, along with our ongoing Phase 3 trial in #SHTG, will evaluate the safety and efficacy of our investigational #FGF21 analog and bring us one step closer to delivering this potential best-in-class therapy to patients. Learn more about the recent advancements we’ve made in our clinical development pipeline: https://lnkd.in/guaY8Zz #MASH #Innovation #SHTG